Phase 2 prospective open label study of neoadjuvant nab-paclitaxel, trastuzumab, and pertuzumab in patients with HER2-positive primary breast cancer.
Sayeh M LavasaniGeorge SomloSusan E YostPaul H FrankelChristopher RuelYujie CuiMireya MurgaAileen TangNorma MartinezLaura KruperLusine TumyanDaniel SchmolzeChristina YeonYuan YuanJames R WaismanJoanne E MortimerPublished in: Cancer (2022)
This anthracycline/carboplatin-free regimen with nab-paclitaxel achieved a pCR rate of 64% in patients with HER2+ BC. The 5-year iDFS in patients with and without pCR was 96.3% and 74.3%, respectively. The pCR rate is comparable with docetaxel, carboplatin, trastuzumab, and pertuzumab therapy in the NAT setting, but with fewer treatment-associated toxicities. This finding suggests the possibility of safe avoidance of anthracyclines and carboplatin as components of NAT in patients with HER2+ BC.
Keyphrases
- epidermal growth factor receptor
- phase ii study
- advanced non small cell lung cancer
- open label
- metastatic breast cancer
- locally advanced
- phase iii
- rectal cancer
- tyrosine kinase
- real time pcr
- clinical trial
- squamous cell carcinoma
- radiation therapy
- phase ii
- randomized controlled trial
- study protocol
- stem cells
- young adults